TNF-α -857 and -1031 polymorphisms predict good therapeutic response to TNF-α blockers in Chinese Han patients with ankylosing spondylitis

Pharmacogenomics

Volumn 13, Issue 13, 2012, Pages 1459-1467

  Tong, Qiang ^a   Zhao, Dong Bao ^a   Bajracharya, Punam ^b   Xu, Xia ^a   Kong, Rui Na ^a   Zhang, Ju ^a   Dai, Sheng Ming ^a   Cai, Qing ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Shree Birendra Hospital   (Nepal)

Author keywords

ankylosing spondylitis; polymorphis; therapeutic respons; TNF ; TNF blockers

Indexed keywords

INFLIXIMAB; RECOMBINANT HUMAN TUMOR NECROSIS FACTOR ALPHA RECEPTOR 2 IMMUNOGLOBULIN G FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; YISAIPU;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CHINESE HAN; CLINICAL ASSESSMENT; CONTROLLED STUDY; DNA POLYMORPHISM; ETHNIC GROUP; FEMALE; GENE; GENE FUNCTION; GENE LOCATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; TNF ALPHA GENE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; CASE-CONTROL STUDIES; CHINA; DNA PRIMERS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84867504980     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.133     Document Type: Article

References (42)

1. Huang F, Zhang J, Huang JL, et al. A multicenter, double-blind, placebo-controlled, randomized, Phase III clinical study of etanercept in treatment of ankylosing spondylitis. Chin. J. Intern. Med. 49(9), 741-745 (2010)
2. Pavy S, Toonen EJ, Miceli-Richard C, et al. Tumour necrosis factor ? -308G->A polymorphism is not associated with response to TNF ? blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann. Rheum. Dis 69(6), 1022-1028 (2010)
3. Seitz M, Wirthmüller U, Möller B, Villiger PM. The -308 tumour necrosis factor-? gene polymorphism predicts therapeutic response to TNF ?-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 46(1), 93-96 (2007).
4. Lee YH, Ji JD, Bae SC, Song GG. Associations between tumor necrosis factor-? (TNF) -308 and -238 G/A polymorphisms and shared epitope status and responsiveness to TNF blockers in rheumatoid arthritis: a metaanalysis update. J. Rheumatol. 37(4), 740-746 (2010)
5. Ingegnoli F, Favalli EG, Meroni PL. Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to TNF ? blocking agents?. A review analysis of the literature. Autoimmun. Rev. 10(8), 460-463 (2011)
6. Liu C, Batliwalla F, Li W, et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol. Med. 14(9-10), 575-581 (2008)
7. Lequerré T, Vittecoq O, Le Loët X. Comments about the editorial by Bénédicte Mugnier and Jean Roudier entitled Factors predicting responsiveness to anti-TNFalpha therapy in patients with rheumatoid arthritis: using biotherapies rationally. Joint Bone Spine 72(4), 346-347 (2005)
8. Balog A, Klausz G, Gál J, et al. Investigation of the prognostic value of TNF gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF production and apoptosis. Pathobiology 71(5), 274-280 (2004)
9. Vasilopoulos Y, Manolika M, Zafiriou E, et al. Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population. Mol. Diagn. Ther. 16(1), 29-34 (2012)
10. Prajapati R, Plant D, Barton A. Genetic and genomic predictors of anti-TNF response. Pharmacogenomics 12(11), 1571-1585 (2011)
11. Sousa E, Caetano-Lopes J, Pinto P, et al. Ankylosing spondylitis susceptibility and severity - contribution of TNF gene promoter polymorphisms at positions -238 and -308. Ann. NY Acad. Sci. 1173, 581-588 (2009)
12. Fonseca JE, Carvalho T, Cruz M, et al. Polymorphism at position -308 of the tumour necrosis factor ? gene and rheumatoid arthritis pharmacogenetics. Ann. Rheum. Dis 64(5), 793-794 (2005)
13. Lee YH, Song GG. Lack of association of TNF promoter polymorphisms with ankylosing spondylitis: a meta-analysis. Rheumatology (Oxford) 48(11), 1359-1362 (2009)
14. Romero-Sánchez C, Londoño J, Delgado G, et al. Association of tumor necrosis factor ?-308 promoter polymorphism with spondyloarthritides patients in Colombia. Rheumatol. Int. 32(7), 2195-2197 (2012)
15. Chatzikyriakidou A, Georgiou I, Voulgari PV, Drosos AA. The role of tumor necrosis factor (TNF)-? and TNF receptor polymorphisms in susceptibility to ankylosing spondylitis. Clin. Exp. Rheumatol. 27(4), 645-648 (2009)
16. Li B, Wang P, Li H. The association between TNF promoter polymorphisms and ankylosing spondylitis: a meta-analysis. Clin. Rheumatol. 29(9), 983-990 (2010)
17. Poddubnyy DA, Märker-Hermann E, Kaluza-Schilling W, et al. Relation of HLA-B27, tumor necrosis factor-? promoter gene polymorphisms, and T cell cytokine production in ankylosing spondylitis-a comprehensive genotype-phenotype analysis from an observational cohort. J. Rheumatol. 38(11), 2436-2441 (2011)
18. Zinovieva E, Bourgain C, Kadi A, et al. Comprehensive linkage and association analyses identify haplotype, near to the TNFSF15 gene, significantly associated with spondyloarthritis. PLoS Genet. 5(6), e1000528 (2009)
19. Lu MC, Yang KL, Tung CH, et al. Higher LPS-stimulated TNF mRNA levels in peripheral blood mononuclear cells from Chinese ankylosing spondylitis patients with -308G/A polymorphism in promoter region of tumor necrosis factor: association with distinct A33/B58/Cw10haplotypes. Rheumatol. Int. 29(2), 189-195 (2008)
20. Brown MA. Re: Zhu et al, A novel gene variation of TNF alpha associated with ankylosing spondylitis: a reconfirmed study. Ann. Rheum. Dis 67(3), 434; discussion 434-436 (2008)
21. Nicknam MH, Mahmoudi M, Amirzargar AA, Jamshidi AR, Rezaei N, Nikbin B. HLA-B27 subtypes and tumor necrosis factor ? promoter region polymorphism in Iranian patients with ankylosing spondylitis. Eur. Cytokine Netw. 20(1), 17-20 (2009)
22. Shiau MY, Lo MK, Chang CP, Yang TP, Ho KT, Chang YH. Association of tumour necrosis factor ? promoter polymorphisms with ankylosing spondylitis in Taiwan. Ann. Rheum. Dis 66(4), 562-563 (2007)
23. Vargas-Alarcón G, Casasola-Vargas J, Rodríguez-Pérez JM, et al. Tumor necrosis factor-? promoter polymorphisms in Mexican patients with spondyloarthritis. Hum. Immunol. 67(10), 826-832 (2006)
24. Davidson SI, Liu Y, Danoy PA, et al. Association of STAT3 and TNFRSF1A with AS in Han Chinese; ARD 2011-investigating the susceptibility to AS in Han Chinese. Ann. Rheum. Dis 70(2), 289-292 (2011)
25. Huang F, Zhang F, Zheng Y, et al. A multicenter, double-blind, randomized, placebo-controlled clinical trial of etanercept treatment of Chinese patients with active ankylosing spondylitis. Chin. J. Intern. Med. 50(12), 1043-1047 (2011)
26. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum. 27(4), 361-368 (1984)
27. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J. Rheumatol. 21(12), 2286-2291 (1994)
28. Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 44(8), 1876-1886 (2001)
29. Chung WT, Choe JY, Jang WC, et al. Polymorphisms of tumor necrosis factor-? promoter region for susceptibility to HLA-B27-positive ankylosing spondylitis in Korean population. Rheumatol. Int. 31(9), 1167-1175 (2011)
30. Marotte H, Arnaud B, Diasparra J, Zrioual S, Miossec P. Association between the level of circulating bioactive tumor necrosis factor ? and the tumor necrosis factor ? gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor ? inhibitor. Arthritis Rheum. 58(5), 1258-1263 (2008)
31. Kooloos WM, Wessels JA, van der Straaten T, Huizinga TW, Guchelaar HJ. Criteria for the selection of single nucleotide polymorphisms in pathway pharmacogenetics: TNF inhibitors as a case study. Drug Discov. Today 14(17-18), 837-844 (2009)
32. Lv K, Chen R, Cai Q, Fang M, Sun S. Effects of a single nucleotide polymorphism on the expression of human tumor necrosis factor-?. Scand. J. Immunol. 64(2), 164-169 (2006)
33. Guis S, Balandraud N, Bouvenot J, et al. Influence of -308 A/G polymorphism in the tumor necrosis factor ? gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum. 57(8), 1426-1430 (2007)
34. Aguillón JC, Cruzat A, Aravena O, Salazar L, Llanos C, Cuchacovich M. Could single-nucleotide polymorphisms (SNPs) affecting the tumour necrosis factor promoter be considered as part of rheumatoid arthritis evolution?. Immunobiology 211(1-2), 75-84 (2006)
35. Soto L, Sabugo F, Catalan D, et al. The presence of anti-citrullinated protein antibodies (ACPA) does not affect the clinical response to adalimumab in a group of RA patients with the tumor necrosis factor (TNF) ?-308 G/G promoter polymorphism. Clin. Rheumatol. 30(3), 391-395 (2011)
36. Plant D, Bowes J, Potter C, et al. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum. 63(3), 645-653 (2011)
37. Suarez-Gestal M, Perez-Pampin E, Calaza M, Gomez-Reino JJ, Gonzalez. A Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study. Arthritis Res. Ther. 12(2), R72 (2010)
38. Potter C, Gibbons LJ, Bowes JD, et al. Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response. Pharmacogenet. Genomics 20(5), 338-341 (2010)
39. O'Rielly DD, Roslin NM, Beyene J, Pope A, Rahman P. TNF-308 G/A polymorphism and responsiveness to TNF blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. Pharmacogenomics J. 9(3), 161-167 (2009)
40. Maxwell JR, Potter C, Hyrich KL, et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum. Mol. Genet. 17(22), 3532-3538 (2008)
41. Ongaro A, De Mattei M, Pellati A, et al. Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNF? therapy in rheumatoid arthritis?. Rheumatol. Int. 28(9), 901-908 (2008)
42. Kang CP, Lee KW, Yoo DH, Kang C, Bae SC. The influence of a polymorphism at position -857 of the tumour necrosis factor a gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology 44(4), 547-552 (2005).